Current Medication Practices and Preferences Among Patients With Psoriatic Arthritis. Issue 2 (March 2022)

• Record Type: Journal Article
• Authors: Schwartzman, Monica; Abutalib, Zafir; Mandl, Lisa A.
• Is Part Of: Journal of clinical rheumatology. Volume 28:Issue 2(2022)
• Publication Date: 2022-03
• Subjects: psoriatic arthritis -- patient preferences -- medication use -- practice guidelines -- disease-modifying antirheumatic drugs; Rheumatism -- Periodicals; Rheumatology -- Periodicals; Musculoskeletal system -- Diseases -- Periodicals; Musculoskeletal Diseases -- Periodicals; Rheumatic Diseases -- Periodicals; Rhumatisme -- Périodiques; Rhumatologie -- Périodiques; Appareil locomoteur -- Maladies -- Périodiques; Musculoskeletal system -- Diseases; Rheumatism; Rheumatology; Periodicals; 616.723005
• DOI: 10.1097/RHU.0000000000001799
• Languages: English
• ISSNs: 1076-1608

Abstract

Abstract : Objective: The aim of this study was to evaluate real-world psoriatic arthritis (PsA) medication use and patient medication preferences. Methods: This is a cross-sectional survey of Classification for Psoriatic Arthritis criteria defined PsA patients recruited from a single-center PsA registry from June to September 2020. Preferences were ranked on a 5-point Likert scale ranging from "not at all important" to "extremely important." Results: One hundred thirty-seven patients (29%) responded. The median duration (years) of PsA skin and joint symptoms was 19 (interquartile range, 10–34) and 12 (interquartile range, 8–21), respectively. The most common initial immunomodulatory medications were anti–tumor necrosis factor α (35%), methotrexate (19%), and anti–phosphodiesterase 4 (anti-PDE4) (12.4%). At survey administration, the most common immunomodulatory therapies were anti–tumor necrosis factor α (30%), anti–interleukin 17 (IL-17) (20.4%), and methotrexate (10.2%). After 2018, when updated guidelines from the American College of Rheumatology/National Psoriasis Foundation were published, a significantly higher percentage of patients' first medication was an anti–IL-17 compared with 2018 or earlier (30% vs 3.5%, p < 0.001), a pattern also seen with anti-PDE4 (40% vs 11.5%, p < 0.012). Medication preferences most ranked as "extremely" important were prevention of joint damage (80%), ability to perform daily activities (71%), prevention of pain (70.1%), rheumatologist recommendation (63%), and medication adverse effects (62%). Conclusions: The significant increase of anti–IL-17 and anti-PDE4 medications as initial treatment after 2018 may reflect their inclusion as potential initial therapy in updated guidelines, along with the importance placed by patients on medication adverse effects. Given the expanding armamentarium of PsA medications, it is increasingly important to align patient preferences and therapeutic options to ensure durable use of effective therapy.